NKTR Shares Surge: Wall Street Predicts Up to 200% Growth Following Impressive Skin Trial Results Exceeding Bullish Expectations

Written by Emily J. Thompson, Senior Investment Analyst

Source: stocktwits

Updated: Feb 11 2026

0mins

Source: stocktwits

Stock Surge: Nektar Therapeutics (NKTR) shares surged by over 51% following positive trial results for Rezpegaldelesleukin, with analysts raising price targets significantly, indicating a potential upside of 170-200%.
Public Offering: Nektar announced a $300 million public offering to fund research and Phase 3 trials for Rezpegaldelesleukin, with proceeds aimed at general corporate purposes.
Analyst Ratings: Analysts upgraded Nektar's stock rating to 'Outperform' and increased price targets, reflecting confidence in the company's sustained efficacy and deepening responses in treatment.
Market Sentiment: Retail sentiment for NKTR shifted from 'bullish' to 'extremely bullish' after trial results, with significant increases in message volume and discussions about the stock's potential.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free